Suboptimal responses in chronic myeloid leukemia-Reference-Cited by-同舟云学术

Suboptimal responses in chronic myeloid leukemia

Published:2011-10-28 Issue:5 Volume:118 Page:1181-1191
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Jabbour Elias¹,Saglio Giuseppe²,Hughes Timothy P.³,Kantarjian Hagop¹

Affiliation:

1. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas

2. Division of Internal Medicine and Hematology, University of Turin and San Luigi Gonzaga Hospital, Orbassano, Italy

3. SA Pathology, University of Adelaide, Adelaide, Australia

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.26391

Reference72 articles.

1. American Cancer Society. Cancer Facts and Figures 2010. Available at:http://www.cancer.org/acs/groups/content/@ epidemiologysurveilance/documents/document/acspc‐026238.pdfAccessed on September 1 2010.

2. AltekruseS KosaryC KrapchoM et al. SEER Cancer Statistics Review 1975‐2007 National Cancer Institute. Available at:http://seer.cancer.gov/statfacts/html/cmyl.htmlAccessed November 9 2010.

3. Transposition of 9q34 and 22 (q11?qter) regions has a specific role in chronic myelocytic leukemia

4. Structural organization of the bcr gene and its role in the Ph′ translocation

5. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype;British Journal of Haematology;2022-07-08

2. Plasma imatinib levels and ABCB1 polymorphism influences early molecular response and failure-free survival in newly diagnosed chronic phase CML patients;Scientific Reports;2020-11-26

3. Generalized finite mixture of multivariate regressions with applications to therapeutic biomarker identification;Statistics in Medicine;2020-08-28

4. Evaluation of Molecular Response to Imatinib Mesylate Treatment in Iranian Patients With Chronic Myeloid Leukemia;Clinical Lymphoma Myeloma and Leukemia;2020-01

5. Comparative analyses of nilotinib versus high-dose imatinib versus sustained standard-dose imatinib in patients with chronic phase chronic myeloid leukemia following suboptimal molecular response to first-line imatinib;Leukemia Research;2018-07